Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Stephen Opat"'
Autor:
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Chan Y. Cheah, Nunzio Franco, Bianca Nguyen, Howard Mutsando, Fatima Tahir, Judith Trotman, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, Stephen Opat, Zoe K. McQuilten, Erica M. Wood, Gayathri St George, Eliza A. Hawkes
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Follicular Lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL pati
Externí odkaz:
https://doaj.org/article/cfa735fb9c744d6191d21946d8605230
Autor:
Christopher R. Flowers, Matthew J. Matasar, Alex F. Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, Marek Trnňný, Lisa Musick, Jamie Hirata, Annie Yang, Laurie H. Sehn
Publikováno v:
Haematologica, Vol 109, Iss 4 (2023)
Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment
Externí odkaz:
https://doaj.org/article/831f0cfd181940158d1d3914f1090dfd
Autor:
Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter S. Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepluch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 106, Iss 9 (2020)
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-ge
Externí odkaz:
https://doaj.org/article/8f75524183cd439aaa1541ae95718eb4